DK1586322T3 - Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer - Google Patents
Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancerInfo
- Publication number
- DK1586322T3 DK1586322T3 DK05014759T DK05014759T DK1586322T3 DK 1586322 T3 DK1586322 T3 DK 1586322T3 DK 05014759 T DK05014759 T DK 05014759T DK 05014759 T DK05014759 T DK 05014759T DK 1586322 T3 DK1586322 T3 DK 1586322T3
- Authority
- DK
- Denmark
- Prior art keywords
- thalidomide
- compounds
- dextamethasone
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2870896P | 1996-11-05 | 1996-11-05 | |
US96305897A | 1997-11-03 | 1997-11-03 | |
PCT/US1997/020116 WO1998019649A2 (en) | 1996-11-05 | 1997-11-04 | Methods and compositions for inhibition of angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1586322T3 true DK1586322T3 (da) | 2008-12-01 |
Family
ID=26703997
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07121971.1T DK1920773T3 (da) | 1996-11-05 | 1997-11-04 | Thalidomid og dexamethason til behandling af tumorer |
DK97946884T DK0963200T3 (da) | 1996-11-05 | 1997-11-04 | Præparater til inhibering af angiogenese omfattende thalidomid og et NSAID |
DK05014759T DK1586322T3 (da) | 1996-11-05 | 1997-11-04 | Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07121971.1T DK1920773T3 (da) | 1996-11-05 | 1997-11-04 | Thalidomid og dexamethason til behandling af tumorer |
DK97946884T DK0963200T3 (da) | 1996-11-05 | 1997-11-04 | Præparater til inhibering af angiogenese omfattende thalidomid og et NSAID |
Country Status (13)
Country | Link |
---|---|
US (4) | US20030191098A1 (da) |
EP (5) | EP1586322B1 (da) |
JP (2) | JP2002513391A (da) |
AT (3) | ATE493983T1 (da) |
AU (4) | AU746713B2 (da) |
CA (2) | CA2270887C (da) |
DE (3) | DE69734290T2 (da) |
DK (3) | DK1920773T3 (da) |
ES (2) | ES2253787T3 (da) |
HK (2) | HK1083064A1 (da) |
NZ (1) | NZ336035A (da) |
PT (2) | PT1920773E (da) |
WO (1) | WO1998019649A2 (da) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
EP1586322B1 (en) * | 1996-11-05 | 2008-08-20 | The Children's Medical Center Corporation | Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9; |
WO2000002555A1 (en) * | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
US6235782B1 (en) * | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
WO2000027404A1 (en) * | 1998-11-12 | 2000-05-18 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
TR200102688T2 (tr) | 1999-03-18 | 2002-01-21 | Celgene Corporation | İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları. |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
JP4920134B2 (ja) * | 1999-05-07 | 2012-04-18 | ジョンズ ホプキンス ユニヴァーシティ スクール オヴ メディシン | 眼障害の処置におけるプロテインチロシンキナーゼ経路インヒビターの使用 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
WO2000072836A2 (en) * | 1999-05-27 | 2000-12-07 | The Rockefeller University | Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
US7105560B1 (en) * | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
US7105172B1 (en) * | 1999-11-18 | 2006-09-12 | Bolla John D | Treatment of rosacea |
KR100777195B1 (ko) * | 2000-04-03 | 2007-11-19 | 산텐 세이야꾸 가부시키가이샤 | 송달성 물질 및 이를 이용한 약물 송달 시스템 |
EP1282423A2 (en) * | 2000-05-11 | 2003-02-12 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
EP1368009A2 (en) * | 2000-07-27 | 2003-12-10 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
AU2002253795B2 (en) * | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
US6344479B1 (en) * | 2001-03-20 | 2002-02-05 | Farmacon-Il, Llc | Method of preventing retinopathy of prematurity in a neonate |
EP1380302B1 (en) * | 2001-03-28 | 2008-08-20 | Santen Pharmaceutical Co., Ltd. | Remedies for retina and choroid diseases containing steroids as the active ingredient |
DK1423115T3 (da) * | 2001-08-06 | 2009-06-15 | Childrens Medical Center | Nitrogen-substituerede thalidomidanalogers antiangiogenetiske aktivitet |
CN1318093C (zh) * | 2001-09-28 | 2007-05-30 | 参天制药株式会社 | 含与聚乙二醇结合的药物的眼组织注射剂 |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
CA2476983C (en) * | 2002-05-17 | 2011-01-25 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
NZ570777A (en) * | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
BR0315316A (pt) * | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
MXPA05004488A (es) * | 2002-10-31 | 2005-07-26 | Celgene Corp | Composicion para el tratamiento de la degeneracion macular. |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
CA2808646C (en) | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
AU2004288714A1 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
MXPA06010699A (es) * | 2004-03-22 | 2006-12-15 | Celgene Corp | Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel. |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
CN1972686A (zh) * | 2004-04-14 | 2007-05-30 | 细胞基因公司 | 选择性细胞因子抑制药在髓发育不良综合征中的用途 |
AU2004319758A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US20050239842A1 (en) * | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
KR101224368B1 (ko) * | 2004-06-04 | 2013-01-22 | 더 스크립스 리서치 인스티튜트 | 혈관신생 질환 치료용 조성물 및 방법 |
AU2005307772B2 (en) * | 2004-11-16 | 2010-06-10 | Limerick Biopharma, Inc. | Methods and compositions for treating pain |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
MX2007006063A (es) * | 2004-11-23 | 2007-07-11 | Celgene Corp | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central. |
MX2007009335A (es) * | 2005-02-02 | 2007-12-07 | Nexgenix Pharmaceuticals L L C | Tratamiento local de neurofibromas. |
US7442690B2 (en) * | 2005-03-14 | 2008-10-28 | P & L Enterprise Llc | Topical treatment for psoriasis |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
CA2615975C (en) * | 2005-07-22 | 2012-11-27 | The Procter & Gamble Company | Compositions for reducing the incidence of drug induced arrhythmia |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
JP5745208B2 (ja) | 2005-10-18 | 2015-07-08 | アラーガン インコーポレイテッドAllergan,Incorporated | 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
EP1974739A1 (en) * | 2007-03-21 | 2008-10-01 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Methods and compounds for modulating inflammatory processes |
US7893045B2 (en) * | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
US20100324107A1 (en) * | 2007-12-12 | 2010-12-23 | Universidade Estadual De Campinas - Unicamp | USE OF PHTHALIMIDE AND/OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF DISEASES WHICH REQUIRE REDUCING THE TNF-alpha LEVELS AND AN EXOGENOUS SOURCE OF NITRIC OXIDE, PHTHALIMIDE DERIVATIVES, SULPHONAMIDE DERIVATIVES, AND A METHOD FOR OBTAINING A SULPHONAMIDE DERIVATIVE |
CA2711582A1 (en) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
BRPI0901298A2 (pt) * | 2009-04-06 | 2011-01-04 | Ems Sa | derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias |
US20120295979A1 (en) * | 2011-05-03 | 2012-11-22 | Florida Atlantic University | Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
WO2014160702A1 (en) | 2013-03-25 | 2014-10-02 | Chs Pharma, Inc. | Retinopathy treatment |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
MA40687A (fr) * | 2014-04-10 | 2017-03-28 | Ifom Fondazione St Firc Di Oncologia Molecolare | Méthodes et compositions de traitement de malformation vasculaire |
KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
SI3313818T1 (sl) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
WO2017081676A1 (en) * | 2015-11-09 | 2017-05-18 | Pharmatwob | Pharmaceutical compositions and methods for treatment of cancer |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
JP2020533383A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
CA3119343C (en) | 2018-11-13 | 2024-01-16 | Biotheryx, Inc. | Substituted isoindolinones |
KR102143531B1 (ko) * | 2018-12-20 | 2020-08-12 | 영남대학교 산학협력단 | 탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물 |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
US3560495A (en) * | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
US3563986A (en) * | 1965-10-12 | 1971-02-16 | Ernst Frankus | 4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6 |
AT278739B (de) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren |
US3705162A (en) * | 1967-07-01 | 1972-12-05 | Gruenenthal Chemie | 4-phthalimidine glutarimides |
US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
IL67646A0 (en) | 1982-01-15 | 1983-05-15 | Lilly Co Eli | Ascorbic acid ethers and related compounds |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
JP2544136B2 (ja) | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤 |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
EP0325199B1 (en) | 1988-01-19 | 1993-10-27 | Takeda Chemical Industries, Ltd. | Fumagillin as angiostatic agent |
US5021404A (en) * | 1988-04-20 | 1991-06-04 | The Children's Medical Center Corporation | Angiostatic collagen modulators |
ATE106726T1 (de) | 1988-09-01 | 1994-06-15 | Takeda Chemical Industries Ltd | Angiogenese hemmendes mittel. |
GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
CA2104776C (en) | 1991-04-17 | 2003-12-09 | Kurt Eger | Thalidomide derivatives, method of manufacture and use thereof in medicaments |
JPH05310576A (ja) * | 1992-04-30 | 1993-11-22 | Shibuya Miyuki | 抗腫瘍剤 |
US5679696A (en) * | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
CA2094203A1 (en) * | 1993-04-16 | 1994-10-17 | Derek A. Willoughby | Inhibition of angiogenesis |
DE4320157A1 (de) * | 1993-06-18 | 1994-12-22 | Bayer Ag | Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
WO1995004533A2 (en) * | 1993-08-04 | 1995-02-16 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5443824A (en) * | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
EP1586322B1 (en) * | 1996-11-05 | 2008-08-20 | The Children's Medical Center Corporation | Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9; |
EP1182709A1 (en) | 2000-08-14 | 2002-02-27 | IPU, Instituttet For Produktudvikling | A process for depositing metal contacts on a buried grid solar cell and a solar cell obtained by the process |
-
1997
- 1997-11-04 EP EP05014759A patent/EP1586322B1/en not_active Expired - Lifetime
- 1997-11-04 EP EP97946884A patent/EP0963200B9/en not_active Expired - Lifetime
- 1997-11-04 PT PT07121971T patent/PT1920773E/pt unknown
- 1997-11-04 EP EP07121971A patent/EP1920773B1/en not_active Expired - Lifetime
- 1997-11-04 CA CA002270887A patent/CA2270887C/en not_active Expired - Lifetime
- 1997-11-04 AT AT07121971T patent/ATE493983T1/de active
- 1997-11-04 DE DE69734290T patent/DE69734290T2/de not_active Expired - Lifetime
- 1997-11-04 WO PCT/US1997/020116 patent/WO1998019649A2/en active IP Right Grant
- 1997-11-04 DK DK07121971.1T patent/DK1920773T3/da active
- 1997-11-04 CA CA2514681A patent/CA2514681C/en not_active Expired - Lifetime
- 1997-11-04 NZ NZ336035A patent/NZ336035A/en not_active IP Right Cessation
- 1997-11-04 AT AT97946884T patent/ATE305301T1/de active
- 1997-11-04 AT AT05014759T patent/ATE405268T1/de active
- 1997-11-04 AU AU51973/98A patent/AU746713B2/en not_active Expired
- 1997-11-04 DE DE69740095T patent/DE69740095D1/de not_active Expired - Lifetime
- 1997-11-04 ES ES97946884T patent/ES2253787T3/es not_active Expired - Lifetime
- 1997-11-04 ES ES05014759T patent/ES2313154T3/es not_active Expired - Lifetime
- 1997-11-04 JP JP52172898A patent/JP2002513391A/ja not_active Withdrawn
- 1997-11-04 DK DK97946884T patent/DK0963200T3/da active
- 1997-11-04 EP EP20090174381 patent/EP2143444A1/en not_active Withdrawn
- 1997-11-04 DK DK05014759T patent/DK1586322T3/da active
- 1997-11-04 EP EP10178851A patent/EP2298300A1/en not_active Withdrawn
- 1997-11-04 DE DE69738935T patent/DE69738935D1/de not_active Expired - Lifetime
- 1997-11-04 PT PT05014759T patent/PT1586322E/pt unknown
-
2000
- 2000-06-14 HK HK06104412A patent/HK1083064A1/xx not_active IP Right Cessation
- 2000-06-14 HK HK00103555A patent/HK1028874A1/xx not_active IP Right Cessation
-
2002
- 2002-03-08 AU AU23191/02A patent/AU780296B2/en not_active Expired
-
2003
- 2003-01-10 US US10/340,554 patent/US20030191098A1/en not_active Abandoned
- 2003-05-05 US US10/430,892 patent/US20040248820A1/en not_active Abandoned
-
2005
- 2005-06-15 AU AU2005202596A patent/AU2005202596B2/en not_active Expired
-
2006
- 2006-04-26 US US11/411,230 patent/US7435745B2/en not_active Expired - Fee Related
-
2008
- 2008-10-10 US US12/249,847 patent/US8039488B2/en not_active Expired - Fee Related
- 2008-10-15 JP JP2008266428A patent/JP5066505B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-18 AU AU2010200186A patent/AU2010200186B2/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1586322T3 (da) | Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer | |
DK0862424T3 (da) | Farmaceutiske præparater omfattende flurbiprofen | |
ATE208397T1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
CA2512926A1 (en) | Methods and compositions for inhibition of angiogenesis | |
HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
BRPI9701248B1 (pt) | Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos | |
ZA908775B (en) | Pharmaceutical compositions and methods for treating the symptoms of overindulgence | |
TR199901101T2 (xx) | Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler. | |
CA2244134A1 (en) | Diphenyl stilbenes as prodrugs to cox-2 inhibitors | |
IL127143A0 (en) | Phospholipid terivatives of non-steroidal anti inflammatory drugs | |
NZ292388A (en) | S-enantiomers of 2-alkyl substituted pentynoic acid derivatives, preparation and pharmaceutical compositions thereof | |
DE69934113D1 (de) | Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen | |
PT1077694E (pt) | Produtos terapeuticos de arilnitrona para o tratamento da doenca inflamatoria dointestino | |
ATE252903T1 (de) | Arzneimittel zur behandlung konvulsivischer zustände | |
NO993126L (no) | Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner | |
SE8504612L (sv) | Analgetiska och antiinflammatoriska kompositioner innefattande difenhydramin och forfaranden for anvendning av dessa | |
MA26484A1 (fr) | Nouveau medicament pour traitement des hemorroides par voie orale. |